Table 1 Clinicopathological relevance of NEK2 in PDAC patients.
From: NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1
Variable | NEK2 | ||
|---|---|---|---|
Low (H-score ≤ 130) | High (H-score > 130) | P value | |
Gender | 0.925 | ||
Male, n (%) | 44(57.9) | 44(57.1) | |
Female, n (%) | 32(42.1) | 33(42.9) | |
Age, years | 0.461 | ||
>60, n (%) | 64(84.2) | 68(88.3) | |
≤60, n (%) | 12(15.8) | 9(11.7) | |
BMI, kg/m2 | 0.238 | ||
<18.5, n (%) | 16(22.2) | 9(12.7) | |
18.5–23.9, n (%) | 35(48.6) | 43(60.6) | |
>23.9, n (%) | 21(29.2) | 19(26.8) | |
TNM stage | 0.239 | ||
I, n (%) | 14(18.4) | 11(14.5) | |
II, n (%) | 40(52.6) | 48(63.2) | |
III, n (%) | 19(25.0) | 11(14.5) | |
IV, n (%) | 3(4.0) | 6(7.9) | |
Vascular invasion | 0.043 | ||
Yes, n (%) | 30(39.0) | 42(55.3) | |
No, n (%) | 47(61.0) | 34(44.7) | |
Nerve invasion | 0.086 | ||
Yes, n (%) | 48(63.2) | 57(76.0) | |
No, n (%) | 28(36.8) | 18(24.0) | |
Serum CA12-5, U/mL | 0.427 | ||
≥35, n (%) | 19(29.2) | 17(23.3) | |
<35, n (%) | 46(70.8) | 56(76.7) | |
Serum CA19-9, U/mL | 0.907 | ||
≥37, n (%) | 63(81.8) | 60(81.1) | |
<37, n (%) | 14(18.2) | 14(18.9) | |
Serum CEA, U/mL | 0.714 | ||
≥5, n (%) | 24(35.8) | 24(32.9) | |
<5, n (%) | 43(64.2) | 49(67.1) | |
Tumor differentiation | 0.045 | ||
Well, n (%) | 3(5.6) | 5(6.8) | |
Moderate, n (%) | 53(72.6) | 39(52.7) | |
Poor, n (%) | 17(23.3) | 30(40.5) | |
Recurrence | 0.982 | ||
Yes, n (%) | 42(72.4) | 39(72.2) | |
No, n (%) | 16(27.6) | 15(27.8) | |
